Navigation Links
New Study Shows Concord Grape Juice has a Heart-Healthy Effect not yet Reported With Red Wine
Date:10/2/2007

CONCORD, Mass., Oct. 2 /PRNewswire/ -- Many studies have suggested that moderate red wine consumption is beneficial to cardiovascular health. But what if you'd like to skip the alcohol? Take heart: laboratory research, just presented at the WINEHEALTH 2007 conference in Bordeaux, France, showed that Concord grape juice stimulated an arterial relaxation effect in a similar fashion to red wine. The French researchers also reported that the Concord grape juice induced a prolonged relaxation effect that has not yet been reported with red wine.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070913/NYTH022LOGO-b )

Dr. Valerie Schini-Kerth and a team of researchers of the Universite Louis Pasteur de Strasbourg, France, found that Concord grape juice stimulated the production of nitric oxide in endothelial cells, providing a vasorelaxation effect. It is known that nitric oxide is important in the body's natural system for maintaining healthy, flexible blood vessels and helps support healthy blood pressure.

Researchers further discovered that Concord grape juice produced this relaxation effect by stimulating the same chemical reactions in the arteries that are activated by red wine. The beneficial effect provided by Concord grape juice lasted up to six hours, whereas this extended effect has not been reported with red wine. This research suggests that the benefits of drinking Concord purple grape juice may last long after finishing the juice.

This research also demonstrates that it's the components of the grape, rather than alcohol, which produce this beneficial effect for the heart.

This study supports other preliminary research in which Concord grape juice had a blood pressure-lowering effect. So, for those looking for an alternative to red wine, grape juice made from Concord grapes provides a delicious, family-friendly, heart-healthy alternative.

Welch Foods Inc. is committed to supporting independent research exploring the role of Concord grape juice in a healthy lifestyle and provided funding and Concord grape juice for this study.


'/>"/>
SOURCE Welch Foods Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... Feb. 4, 2016  SciClone Pharmaceuticals, Inc. (NASDAQ: ... has entered into a settlement agreement with the ... resolving the SEC,s investigation into possible violations of ... terms of the settlement agreement, SciClone has agreed ... disgorgement, pre-judgment interest and a penalty.  This payment ...
(Date:2/4/2016)...  Montoya Love is recognized by Continental Who,s Who ... Montoya is the Regulatory Systems Operations Manager with ... Manufacturing and selling a broad range of ... healthcare institutions, clinical laboratories and life science researchers with ... globe. ...
(Date:2/4/2016)... Feb. 4, 2016 Global Immunology Market ... to drive long-term market growth Summary ... of chronic disorders that affect 5–7% of western ... of their symptoms and key patient demographics, they ... immune pathways and an inappropriate immune response. Generally, ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... ... H. Van Allen have signed a joint enrollment and degree completion agreement. ... toward associate and baccalaureate degrees at FHU|Dickson. , The agreement allows students ...
(Date:2/5/2016)... OR (PRWEB) , ... February 05, 2016 , ... The ... modern technology, such water may be safer than regular municipal or well water. The ... and radio host Sharon Kleyne, could go a long way toward increasing public acceptance ...
(Date:2/5/2016)... ... February 05, 2016 , ... At its annual meeting ... McDermott as Chairman of the National Board of Directors. Mr. McDermott succeeds former APDA ... Board,” stated Leslie A. Chambers , APDA President and CEO. “Pat has tirelessly ...
(Date:2/5/2016)... ... ... In sleep, when the defenses of the day are at rest, rejected emotions ... disorders is significant self-criticism, and consequently these patients experience this disease with their feelings, ... for coping with this unease, but also leads to a reservoir of emotions that ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... inaugural Columbia University Men’s Soccer Career Development event in New York City on ... Rocco Commisso, Chairman and CEO of Mediacom, (both alumnus of the varsity Columbia ...
Breaking Medicine News(10 mins):